8215 RESULTS
COMMENT This pilot study, although small, is very exciting. The fact that many of the patients taking the drug did not show decline in several clinical endpoints measured in the study is promising. The preclinical data available in cell culture models suggest ...
COMMENT This was a randomized, placebo-controlled, double-blinded trial of EH301 (which elevates NAD+ and activates sirtuins) in patients with ALS. The authors concluded that that the drug was safe and associated with significant improvements, not just slowing of ...
COMMENT I do think the data support proceeding to another study. I also encourage the company and investigators to develop biomarkers to measure the biological effects of treatment. It is, of course, exciting to see positive results in an ALS trial. The caveats ...
COMMENT It is very remarkable and encouraging to see that the investigators report a clinical improvement in the ALS patients and not just a slowing of progression of this devastating disease. Findings like these urgently require independent confirmation. One has ...
COMMENT The data shown here seems extraordinary in that the active group seemed to actually “improve” over the four-month trial period. If true, fantastic! But it reminds me a bit of the Italian trial of lithium—amazing results in a small cohort and completely ...
COMMENT In this elegant study, the authors used in vivo two-photon excited fluorescence (2PEF) microscopy to demonstrate that in APP/PS1, 5xFAD, as well as TgCRND8 mice there is capillary stalling that does not change with advancement of Aβ plaque pathology or in ...
COMMENT With interest we have read the article of Hernández and colleagues investigating the underlying mechanism behind the observation of reduced cerebral blood flow in Alzheimer’s disease. Cerebral blood flow is an interesting measure by which to investigate ...
COMMENT In Alzheimer’s disease, sex differences emerged from different studies that focused on diverse aspects of the disease. Indeed, epidemiological and observational studies provide evidence for higher prevalence and incidence of AD in women than in age ...
COMMENT We support the report from Melini et al. Fibrinogen will attract other molecules, especially tissue plasminogen activator (tPA) and plasminogen. In addition, the activation of tPA in brain was shown to be very toxic to neurons (Kaur et al., 2004; Liu et ...
COMMENT The finding that decreased prothrombin was the highest-ranked feature in the Aβ+ cognitively unimpaired cohort is very intriguing. Thrombin derived from prothrombin is the last protease in the blood coagulation cascade. Aβ can activate Factor XII in the ...
COMMENT I notice that everyone is largely in agreement with the findings of the authors. All very exciting. I wish to add that the very sites linked with ApoE and complement activation (atherosclerosis, choroid plexus, amyloid-β plaques) are also known to contain ...
COMMENT We were glad to see Melini et al. show in whole animals an integrated anatomical, physiologic, and cognitive effect of fibrinogen leaks from the plasma into the parenchyma. Now many directions of research confirm what we suspected when we showed how ...
COMMENT We read this paper with great interest. This work provides a novel link between cholesterol esters (CE) with tau pathology in Alzheimer's disease patient-derived neurons. According to the authors, the CE effects on tau proteostasis are independent of ...
COMMENT The finding that blood-derived fibrinogen has direct effects on brain microglia and dendritic spines provides an intriguing mechanism by which cerebrovascular disease may influence cognition. This work tallies well with recent findings that blood brain ...
COMMENT We and others regularly observe a differential profile of blood fibrinogen being associated with brain amyloid pathology and cognitive decline in Alzheimer’s disease patients, without fully understanding its mechanistic importance. Previous reports have ...
